Related Experiment Video
Updated: Jun 15, 2025
Characterization of Intra-Cartilage Transport Properties of Cationic Peptide Carriers
Published on: August 10, 2020
Multifunctional polymeric nanocapsules with enhanced cartilage penetration and retention for osteoarthritis treatment
Hongxiang Mei1, Chuanlu Sha2, Qinyi Lv1
1State Key Laboratory of Oral Diseases, National Center for Stomatology, National Clinical Research Center for Oral Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu 610041, Sichuan, China.
Abstract:
Osteoarthritis (OA) is a prevalent joint disease characterized by cartilage degeneration and subchondral bone homeostasis imbalance. Effective topical OA therapy is challenging, as therapeutic drugs often suffer from insufficient penetration and rapid clearance. We develop miniature polydopamine (PDA) nanocapsules (sub-60 nm), which are conjugated with collagen-binding polypeptide (CBP) and loaded with an anabolic drug (i.e., parathyroid hormone 1-34, PTH 1-34) for efficient OA treatment. Such multifunctional polymeric nanocapsules, denoted as PDA@CBP-PTH, possess deformability when interacting with the dense collagen fiber networks, enabling the efficient penetration into 1 mm cartilage in 4 h and prolonged retention within the joints up to 28 days. Moreover, PDA@CBP-PTH nanocapsules exhibit excellent reactive oxygen species scavenging property in chondrocytes and enhance the anabolism in subchondral bone. The nanosystem, as dual-mode treatment for OA, demonstrates rapid penetration, long-lasting effects, and combinational therapeutic impact, paving the way for reversing the progression of OA for joint health care.
Insights
New polydopamine nanocapsules deliver drugs effectively for osteoarthritis (OA) treatment. These nanocapsules penetrate deep into cartilage, offering prolonged retention and dual therapeutic effects for joint health.
Area of Science:
- Biomaterials Science
- Nanotechnology
- Orthopedics
Background:
- Osteoarthritis (OA) is a degenerative joint disease causing cartilage breakdown and bone imbalance.
- Current topical OA treatments face challenges with drug penetration and short retention times.
Purpose of the Study:
- To develop a novel nanocarrier system for enhanced topical osteoarthritis therapy.
- To improve drug delivery, penetration, and retention within joint tissues.
Main Methods:
- Development of polydopamine (PDA) nanocapsules (sub-60 nm) conjugated with collagen-binding polypeptide (CBP).
- Loading nanocapsules with parathyroid hormone 1-34 (PTH 1-34), an anabolic drug.
- Evaluation of nanocapsule deformability, cartilage penetration, retention time, and therapeutic effects in vitro and in vivo.
Main Results:
- PDA@CBP-PTH nanocapsules demonstrated efficient penetration (1 mm cartilage in 4 h) and prolonged retention (up to 28 days).
- The nanocarrier system showed reactive oxygen species scavenging in chondrocytes.
- Enhanced anabolism in subchondral bone was observed, indicating a dual therapeutic mode.
Conclusions:
- The developed PDA@CBP-PTH nanocarrier system offers a promising dual-mode treatment for osteoarthritis.
- This nanosystem facilitates rapid penetration, sustained release, and combinational therapy for OA.
- The findings suggest a potential strategy for reversing OA progression and improving joint health care.
